Compare VanEck Gold Miners ETF (GDX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? VanEck Gold Miners ETF trades at $85.04 (market cap $26.33B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: VanEck Gold Miners ETF is far larger — about 5.4× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 77 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GDX | TVTX | |
|---|---|---|
Market Cap | $26.33B | $4.88B |
Volume | 15,141,546 | 1,668,577 |
52-Week High | $115.84 | $67.52 |
52-Week Low | $68.28 | $26.79 |
Typical Hold Time | 77 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $87.24, down 1.46% on the day, with technical indicators showing a neutral to bearish bias amid mixed signals from moving averages and oscillators. The ETF's fundamental metrics are not provided in the snapshot, but recent news highlights ongoing institutional repositioning and comparisons between gold miners and physical gold. Support and resistance levels are tightly clustered around the current price, suggesting near-term consolidation.
The outlook for GDX hinges on gold price trends and interest rate movements, with potential upside from inflation hedging demand but risks from institutional selling and metal volatility. Investors face a balanced risk-reward scenario given neutral sentiment and lack of clear directional catalysts.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
